🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yaxia Yuan

The University of Texas at San Antonio Health Science Center

ORCID: 0000-0001-7094-4419

Also affiliated with Drug Discovery Laboratory (Norway), The University of Texas at San Antonio

Biochemistry, Genetics and Molecular BiologyComputer ScienceImmunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/0008-5472.22432374.v1
Top 100%
0DataRank
Top 100%0 citations

Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu +21 more

Papers

Driven by 21 papers — median percentile 0. Top paper: “Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity”.

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Nature Communications(2020)10.1038/s41467-020-15838-0
N/A
0.838DataRank · unranked
266 citations

Xuan Zhang, Jianhui Chang, Ha‐Neui Kim, Peiyi Zhang, Yingying Wang +17 more

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL

Nature Communications(2024)10.1038/s41467-024-46922-4
N/A
0.590DataRank · unranked
50 citations

Dongwen Lv, Yaxia Yuan, Peiyi Zhang, Wanyi Hu, Anindita Nayak +8 more

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c00723
N/A
0.529DataRank · unranked
33 citations

Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou +2 more

PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1

Cell stem cell(2025)10.1016/j.stem.2025.01.010
N/A
0.396DataRank · unranked
13 citations

Pinpin Sui, Ying Li, Kaiyu Xu, Ji‐Hoon Lee, Juan Wang +20 more

FoxM1 insufficiency hyperactivates Ect2–RhoA–mDia1 signaling to drive cancer

Nature Cancer(2020)10.1038/s43018-020-00116-1
N/A
0DataRank · unranked
14 citations

Karthik B. Jeganathan, Jake A. Kloeber, Brian A. Davies, Cheng Zhang, Ines Sturmlechner +10 more

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Nature Communications(2021)10.1038/s41467-021-27210-x
N/A
0DataRank · unranked
149 citations

Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang +19 more

Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat‐inhibited Dopamine Transport

Journal of Neuroimmune Pharmacology(2021)10.1007/s11481-021-09984-5
N/A
0DataRank · unranked
11 citations

Yaxia Yuan, Yike Zhu, Yi Zhou, Matthew J. Strauss, Wei‐Lun Sun +3 more

Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat

ACS Chemical Neuroscience(2021)10.1021/acschemneuro.0c00792
N/A
0DataRank · unranked
6 citations

Yaxia Yuan, Sarah E. Davis, Ciai Lin, Jiahui Xu, Jun Zhu +2 more

A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

Cancer Research(2022)10.1158/0008-5472.can-22-0698
N/A
0DataRank · unranked
27 citations

Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu +21 more

Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function

PLoS ONE(2022)10.1371/journal.pone.0275182
N/A
0DataRank · unranked
6 citations

Katherine D. Porter, Pamela M. Quizon, Sarah E. Davis, Steven Lin, Yaxia Yuan +5 more

Piperlongumine (PL) conjugates induce targeted protein degradation

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.21.474712
N/A
0DataRank · unranked
6 citations

Yufeng Xiao, Xingui Liu, Wanyi Hu, Amin Sobh, Yaxia Yuan +12 more

Piperlongumine conjugates induce targeted protein degradation

Cell chemical biology(2023)10.1016/j.chembiol.2023.01.004
N/A
0DataRank · unranked
71 citations

Yufeng Xiao, Xingui Liu, Wanyi Hu, Amin Sobh, Yaxia Yuan +12 more

Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism

Signal Transduction and Targeted Therapy(2023)10.1038/s41392-023-01373-z
N/A
0DataRank · unranked
17 citations

Zhenzhen Li, Xiaoling Chen, Wenxin Wang, Ting Duan, Louis Scampavia +5 more

TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells

Nucleic Acids Research(2023)10.1093/nar/gkad952
N/A
0DataRank · unranked
15 citations

Arijit Dutta, Gayathri Srinivasan, Yaxia Yuan, Daohong Zhou, Montaser Shaheen +14 more

PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis

Molecular Oncology(2023)10.1002/1878-0261.13539
N/A
0DataRank · unranked
5 citations

Zexuan Liu, Weiwei Tang, Uday P. Pratap, Alexia B. Collier, Kristin A. Altwegg +12 more

Supplementary Table from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer

INDIGO (University of Illinois at Chicago)(2023)10.1158/0008-5472.22432374.v1
Top 100%
0DataRank
Top 100%0 citations

Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu +21 more

Ewing sarcoma depends on C4orf48/NICOL, a NELL2 cofactor regulated by Hippo signaling

Cellular Signalling(2025)10.1016/j.cellsig.2025.111904
N/A
0DataRank · unranked
1 citations

Xiuye Ma, Yidong Chen, Yaxia Yuan, Yuzuru Shiio, Panneerselvam Jayabal

Computational Design and In Vitro and In Vivo Characterization of an ApoE-Based Synthetic High-Density Lipoprotein for Sepsis Therapy

Biomolecules(2025)10.3390/biom15030397
N/A
0DataRank · unranked
0 citations

Yaxia Yuan, Fang Zheng, Chang‐Guo Zhan, Xiang‐An Li, Ling Guo

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Journal of Hematology & Oncology(2020)10.1186/s13045-020-00924-z
N/A
0DataRank · unranked
123 citations

Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu +6 more

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112186
N/A
0DataRank · unranked
115 citations

Dinesh Thummuri, Xingui Liu, Wanyi Hu, Peiyi Zhang, Sajid Khan +4 more

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

European Journal of Medicinal Chemistry(2020)10.1016/j.ejmech.2020.112397
N/A
0DataRank · unranked
65 citations

Yonghan He, Peiyi Zhang, Vivekananda Budamagunta, Dongwen Lv, Dinesh Thummuri +6 more